428 related articles for article (PubMed ID: 9779766)
1. Comparative reactogenicity and immunogenicity of booster doses of diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine and diphtheria-tetanus-inactivated poliovirus vaccine in preadolescents.
Bégué PC; Grimprel EM; Giovannangeli MD; Abitbol VI
Pediatr Infect Dis J; 1998 Sep; 17(9):804-9. PubMed ID: 9779766
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults.
Kovac M; Rathi N; Kuriyakose S; Hardt K; Schwarz TF
Vaccine; 2015 May; 33(22):2594-601. PubMed ID: 25882172
[TBL] [Abstract][Full Text] [Related]
3. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
[TBL] [Abstract][Full Text] [Related]
4. Repeated administration of a reduced-antigen-content diphtheria-tetanus-acellular pertussis and poliomyelitis vaccine (dTpa-IPV; Boostrix™ IPV).
Knuf M; Vetter V; Celzo F; Ramakrishnan G; Van Der Meeren O; Jacquet JM
Hum Vaccin; 2010 Jul; 6(7):554-61. PubMed ID: 20448468
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a combined diphtheria, tetanus, acellular pertussis, and inactivated poliovirus vaccine (DTaP-IPV) compared to separate administration of standalone DTaP and IPV vaccines: a randomized, controlled study in infants in the Republic of Korea.
Lee SY; Hwang HS; Kim JH; Kim HH; Lee HS; Chung EH; Park SE; Ma SH; Chang JK; Guitton F; Ortiz E; Kang JH
Vaccine; 2011 Feb; 29(8):1551-7. PubMed ID: 21215828
[TBL] [Abstract][Full Text] [Related]
6. Humoral immunity of dTap-IPV vaccine (REPEVAX®) administered one month after dT-IPV vaccine (REVAXIS®) in adults with unknown vaccination history.
Larnaudie S; Guiso N; Baptiste C; Desaint C; Desforges L; Lebon P; Soubeyrand B; Launay O
Hum Vaccin; 2010 Oct; 6(10):829-34. PubMed ID: 20864810
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and reactogenicity of a booster dose of diphtheria, tetanus, acellular pertussis and inactivated poliomyelitis vaccines given concurrently with Haemophilus type b conjugate vaccine or as pentavalent vaccine.
Bégué P; Stagnara J; Vie-Le-Sage F; Bernard JC; Xerri B; Abitbol V
Pediatr Infect Dis J; 1997 Aug; 16(8):787-94. PubMed ID: 9271042
[TBL] [Abstract][Full Text] [Related]
8. Booster vaccination of pre-school children with reduced-antigen-content diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine co-administered with measles-mumps-rubella-varicella vaccine: a randomized, controlled trial in children primed according to a 2 + 1 schedule in infancy.
Ferrera G; Cuccia M; Mereu G; Icardi G; Bona G; Esposito S; Marchetti F; Messier M; Kuriyakose S; Hardt K
Hum Vaccin Immunother; 2012 Mar; 8(3):355-62. PubMed ID: 22327497
[TBL] [Abstract][Full Text] [Related]
9. Diphtheria-tetanus-acellular pertussis and inactivated poliovirus vaccines given separately or combined for booster dosing at 4-6 years of age.
Black S; Friedland LR; Ensor K; Weston WM; Howe B; Klein NP
Pediatr Infect Dis J; 2008 Apr; 27(4):341-6. PubMed ID: 18316985
[TBL] [Abstract][Full Text] [Related]
10. Antibody persistence to diphtheria toxoid, tetanus toxoid,
Wanlapakorn N; Sarawanangkoor N; Srimuan D; Thatsanathorn T; Thongmee T; Poovorawan Y
Hum Vaccin Immunother; 2024 Dec; 20(1):2352909. PubMed ID: 38752802
[TBL] [Abstract][Full Text] [Related]
11. Safety and immunogenicity of combined Dtpa-IPV vaccine for primary and booster vaccination.
Meriste S; Tamm E; Willems P; Lutsar I
Scand J Infect Dis; 1999; 31(6):587-91. PubMed ID: 10680990
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of a combined diphtheria-tetanus-acellular pertussis-inactivated polio vaccine-Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age.
Carlsson RM; Claesson BA; Selstam U; Fagerlund E; Granström M; Blondeau C; Hoffenbach A
Pediatr Infect Dis J; 1998 Nov; 17(11):1026-33. PubMed ID: 9849987
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age.
Arístegui J; Dal-Ré R; Díez-Delgado J; Marés J; Casanovas JM; García-Corbeira P; De Frutos E; Van Esso D; Verdaguer J; De la Flor J; Moraga F; Boceta R; García-Martínez JA
Vaccine; 2003 Sep; 21(25-26):3593-600. PubMed ID: 12922087
[TBL] [Abstract][Full Text] [Related]
14. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six-month-old Chilean infants.
Lagos R; Kotloff K; Hoffenbach A; San Martin O; Abrego P; Ureta AM; Pines E; Blondeau C; Bailleux F; Levine MM
Pediatr Infect Dis J; 1998 Apr; 17(4):294-304. PubMed ID: 9576383
[TBL] [Abstract][Full Text] [Related]
15. A phase III, open-label, randomised multicentre study to evaluate the immunogenicity and safety of a booster dose of two different reduced antigen diphtheria-tetanus-acellular pertussis-polio vaccines, when co-administered with measles-mumps-rubella vaccine in 3 and 4-year-old healthy children in the UK.
Marlow R; Kuriyakose S; Mesaros N; Han HH; Tomlinson R; Faust SN; Snape MD; Pollard AJ; Finn A
Vaccine; 2018 Apr; 36(17):2300-2306. PubMed ID: 29576304
[TBL] [Abstract][Full Text] [Related]
16. Immunogenicity of a low-dose diphtheria, tetanus and acellular pertussis combination vaccine with either inactivated or oral polio vaccine compared to standard-dose diphtheria, tetanus, acellular pertussis when used as a pre-school booster in UK children: A 5-year follow-up of a randomised controlled study.
John T; Voysey M; Yu LM; McCarthy N; Baudin M; Richard P; Fiquet A; Kitchin N; Pollard AJ
Vaccine; 2015 Aug; 33(36):4579-85. PubMed ID: 26165918
[TBL] [Abstract][Full Text] [Related]
17. [The immunological basis of the administration of DTP-polio vaccine].
Cohen H
Verh K Acad Geneeskd Belg; 2000; 62(4):245-67. PubMed ID: 11004905
[TBL] [Abstract][Full Text] [Related]
18. Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants.
Zepp F; Knuf M; Heininger U; Jahn K; Collard A; Habermehl P; Schuerman L; Sänger R
Vaccine; 2004 Jun; 22(17-18):2226-33. PubMed ID: 15149781
[TBL] [Abstract][Full Text] [Related]
19. Adult formulation of a five component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine is safe and immunogenic in adolescents and adults.
Halperin SA; Smith B; Russell M; Scheifele D; Mills E; Hasselback P; Pim C; Meekison W; Parker R; Lavigne P; Barreto L
Pediatr Infect Dis J; 2000 Apr; 19(4):276-83. PubMed ID: 10783014
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity and safety of a tetravalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus vaccine.
Gyhrs A; Lyngholm E; Larsen SO; Aggerbeck H; Heron I
Scand J Infect Dis; 1999; 31(6):579-85. PubMed ID: 10680989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
